Abstract: The devices, assemblies, and methods described herein utilize photoacoustic principals to create a jet of fluid using a ultrasonic resonance member and a pulsed laser light beam. The ultrasonic resonance member is a treated substrate having an liquid interface surface in contact with a fluid. When a pulsed laser light beam is applied to the treated substrate, pressure is generated via induced ultrasonic waves to urge the fluid into a jet stream.

Abstract: Systems and methods for injecting a drug and detecting tissue induced back pressure are disclosed. A drug delivery system may include a reservoir filled or fillable with a drug, an administration member connected or connectable in fluid communication with the reservoir, a drive assembly, and a pressure sensor. The administration member may be configured for insertion into and subsequently retraction from a patient. The drive assembly may be configured to urge the drug from the reservoir to deliver a dose of the drug to the patient via the administration member. The pressure sensor may be configured to detect tissue back pressure during use of the drug delivery system, including after dose completion and prior to retraction of the administration member. The drug delivery system may be controlled in a manner that accounts for the tissue back pressure measurement.

Abstract: Described herein are compounds of Formula I and pharmaceutically acceptable salt thereof, stereoisomers, tautomers as well as pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity and may have use in treating proliferative, metabolic and blood disorders.

Abstract: The present invention provides a method for manipulating the fucosylated glycan content on a recombinant protein.

Abstract: Methods and pharmaceutical compositions are provided herein for the treatment of inflammatory disorders, in particular celiac disease, refractory celiac disease and non-celiac gluten sensitivity.

Abstract: Provided herein are methods of treating a subject having a neoplastic disease, comprising administering to the subject a KIF18A inhibitor in an amount effective to treat the neoplastic disease a neoplastic disease in a subject. Also provided are methods of inducing or increasing tumor regression in a subject with a tumor and methods of reducing tumor or cancer growth in a subject. In exemplary aspects, the method comprises administering to the subject a KIF18A inhibitor. Methods of inducing or increasing death of tumor or cancer cells in a subject comprising administering to the subject a KIF18A inhibitor are also provided herein. Advantageously, the KIF18A inhibitors selectively treat the neoplastic disease, induce or increase tumor regression, and/or induce or increase death of tumor or cancer cells without overt toxicity to normal somatic cells.

Abstract: Stable adalimumab formulations are disclosed.

Abstract: GDF15 molecules are provided herein. In some embodiments, the GDF15 molecule is a GDF15-Fc fusion, in which a GDF15 region is fused to an Fc region. In some embodiments, the GDF15 region is fused to the Fc region via a linker. Also, provided herein are methods for making and using GDF15 molecules.

Abstract: Novel peptides that bind to human PAC1 are provided. These peptides that are antagonists of PAC1 are useful in a number of PAC1 related disorders, including the treatment and/or prevention of headache disorders, including migraine, such as acute migraine.

Abstract: Provided herein are processes for synthesizing intermediates useful in preparing Mcl-1 inhibitors. In particular, provided herein are processes for synthesizing compound (E), wherein R1 is described herein. Compound (E) can be useful in synthesizing compound (A1), or a salt or solvate thereof, and compound (A2), or a salt of solvate thereof.

Abstract: The present invention relates to bispecific or biparatopic antigen binding proteins, polynucleotides encoding the same, and methods of making bispecific or biparatopic antigen binding proteins. Also described herein is a method to assemble IgG-like biparatopic or bispecific antibodies from VH only antigen binding proteins.

Abstract: Described herein are immunosuppressive molecules including immunosuppressive variants of IL-2, and use of such molecules to treat inflammatory and autoimmune disorders.

Abstract: Described herein are bispecific proteins specific for BAFF and B7RP1, nucleic acids encoding such proteins, methods of making such proteins, and uses for such proteins.

Abstract: The invention provides a method for culturing mammalian cells. The method provides greater control over cell o growth to achieve high product titer cell cultures.

Abstract: The invention provides a method for culturing mammalian cells. The method provides greater control over cell growth to achieve high product titer cell cultures.

Abstract: Provided herein are heterodimeric bispecific antibodies that can mediate cytolysis of a target cell by an immune effector cell, nucleic acids encoding such antibodies, methods of making such antibodies, and methods of using such antibodies. These antibodies comprise two different polypeptide chains, each comprising two immunoglobulin variable regions and, optionally, a half life-extending moiety.